Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

Figure 3

(a) Proportion of patients who did not require a platelet transfusion or rescue for bleeding 7 days post-procedure by individual Baseline platelet count subgroup—pooled data from ADAPT-1 and ADAPT-2 (full analysis set). ^aResponders were defined as patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Note: -values are based on Fisher’s exact test. (b) Proportion of patients achieving the target platelet count of ≥50 × 10⁹/L on Procedure Day by individual Baseline platelet count subgroup—pooled data from ADAPT-1 and ADAPT-2. ^aResponders were defined as proportion of patients achieving the target platelet count of ≥50 × 10⁹/L on Procedure Day. Note: -values are based on Fisher’s exact test. (c) Mean change in platelet count from Baseline to Procedure Day by individual Baseline platelet count subgroup—pooled data from ADAPT-1 and ADAPT-2. Note: -values are based on Wilcoxon rank-sum test.

(a)

(b)

(c)